Background: Appropriately conducted adaptive designs (ADs) offer many potential advantages over conventional trials. They make better use of accruing data, potentially saving time, trial participants, and limited resources compared to conventional, fixed sample size designs. However, one can argue that ADs are not implemented as often as they should be, particularly in publicly funded confirmatory trials. This study explored barriers, concerns, and potential facilitators to the appropriate use of ADs in confirmatory trials among key stakeholders. Methods: We conducted three cross-sectional, online parallel surveys between November 2014 and January 2015. The surveys were based upon findings drawn from in-depth interviews of key research stakeholders, predominantly in the UK, and targeted Clinical Trials Units (CTUs), public funders, and private sector organisations. Response rates were as follows: 30(55 %) UK CTUs, 17(68 %) private sector, and 86(41 %) public funders. A Rating Scale Model was used to rank barriers and concerns in order of perceived importance for prioritisation. Results: Top-ranked barriers included the lack of bridge funding accessible to UK CTUs to support the design of ADs, limited practical implementation knowledge, preference for traditional mainstream designs, difficulties in marketing ADs to key stakeholders, time constraints to support ADs relative to competing priorities, lack of applied training, and insufficient access to case studies of undertaken ADs to facilitate practical learning and successful implementation. Associated practical complexities and inadequate data management infrastructure to support ADs were reported as more pronounced in the private sector. For funders of public research, the inadequate description of the rationale, scope, and decision-making criteria to guide the planned AD in grant proposals by researchers were all viewed as major obstacles. Conclusions: There are still persistent and important perceptions of individual and organisational obstacles hampering the use of ADs in confirmatory trials research. Stakeholder perceptions about barriers are largely consistent across sectors, with a few exceptions that reflect differences in organisations' funding structures, experiences and characterisation of study interventions. Most barriers appear connected to a lack of practical implementation knowledge and applied training, and limited access to case studies to facilitate practical learning.
from #Medicine via ola Kala on Inoreader http://ift.tt/1OafJ9P
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
►
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
-
▼
2015
(2119)
-
▼
Δεκεμβρίου
(940)
-
▼
Δεκ 23
(50)
- Braın abscess due to Streptococcus intermedius sec...
- Terlipressin and albumin for type 1 hepatorenal sy...
- CT-guided biopsy of lung lesions using two needles...
- Evaluation of a systematic approach to weaning of ...
- The impact of system matrix dimension on small FOV...
- Effect of deformable registration uncertainty on l...
- Osmotic potential calculations of inorganic and or...
- Flattening filter free beams from TrueBeam and Ver...
- Discontinuous finite element space-angle treatment...
- Constructing the ecstasy of MDMA from its componen...
- Strategy To Fabricate Naked-Eye Readout Ultrasensi...
- Enhanced Mass Defect Filtering To Simplify and Cla...
- Cross-sector surveys assessing perceptions of key ...
- Diagnosis of early-stage esophageal cancer by Rama...
- Micro movements of the upper limb in fibromyalgia:...
- The curative efficacy of arthroscopic therapy in t...
- Does statin use have a disease modifying effect in...
- Plasmonic nanostructures for surface enhanced spec...
- Study of Oral Ceritinib in Patients With ALK-Activ...
- The neurophysiology of failed visual perceptions: ...
- Life, Vol. 6, Pages 1: Landmarks in the Evolution ...
- Healthcare, Vol. 4, Pages 1: Shortening a Patient ...
- Molbank, Vol. 2016, Article M882: 1,3-Bis(5′-methy...
- Marine Drugs, Vol. 14, Pages 2: In Vitro and in Vi...
- Humanities, Vol. 5, Pages 1: Double Blind Peer-Rev...
- JDB, Vol. 4, Pages 1: Beyond the Mammalian Heart: ...
- Laws, Vol. 5, Pages 1: Services in the Field of La...
- JoF, Vol. 2, Pages 1: Colliding Epidemics and the ...
- Diagnostics, Vol. 6, Pages 2: Ultrasonography of t...
- Insects, Vol. 7, Pages 1: Antagonistic Interaction...
- Making the invisible visible: Improved electrospra...
- Preclinical mouse models for assessing axial compr...
- Role of Irisin on the bone–muscle functional unit
- Skeletal stem cells for bone development, homeosta...
- Sulfiredoxin inhibitor induces preferential death ...
- Down-regulation of the mitochondrial matrix peptid...
- Neuroprotective potential of molecular hydrogen ag...
- ZYZ451 Protects Cardiomyocytes from Hypoxia-induce...
- Caffeic acid prevents acetaminophen-induced liver ...
- Fructose-derived advanced glycation end-products d...
- Polymers, Vol. 8, Pages 1: Comparative Indoor and ...
- Biology, Vol. 5, Pages 1: Cell Adhesion Molecules ...
- Micromachines, Vol. 7, Pages 1: Miniature Microwav...
- Chemosensors, Vol. 4, Pages 1: Building Selectivit...
- Bioengineering, Vol. 3, Pages 1: Sustained Release...
- Cancers, Vol. 8, Pages 2: Diverse Mechanisms of Sp...
- Catalysts, Vol. 6, Pages 1: Catalytic Conversion o...
- Behavioral Sciences, Vol. 6, Pages 1: Adolescent P...
- Minerals, Vol. 6, Pages 1: New Insights in the Ont...
- Algorithms, Vol. 9, Pages 2: Offset-Assisted Facto...
-
▼
Δεκ 23
(50)
-
▼
Δεκεμβρίου
(940)
Αναζήτηση αυτού του ιστολογίου
Τετάρτη 23 Δεκεμβρίου 2015
Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.